Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Molecular and Cellular Biology / Genetics

Abstract LB-301: Integrative genomic analysis identifies distinct mutational, epigenetic and immunological patterns among triple-negative breast cancer subtypes

Brian D. Lehmann, Antonio Colaprico, Jianjiao Chen, Lily Wang, Jennifer Pietenpol and Xi Chen
Brian D. Lehmann
1Vanderbilt University Medical Center, Nashville, TN;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Colaprico
2University of Miami Miller School of Medicine, Miami, FL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianjiao Chen
2University of Miami Miller School of Medicine, Miami, FL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lily Wang
2University of Miami Miller School of Medicine, Miami, FL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Pietenpol
1Vanderbilt University Medical Center, Nashville, TN;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xi Chen
2University of Miami Miller School of Medicine, Miami, FL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2019-LB-301 Published July 2019
  • Article
  • Info & Metrics
Loading
Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA

Abstract

Triple-negative breast cancer is an inherently heterogeneous disease defined by the absence of estrogen receptor, progesterone receptor and human epithelial growth factor receptor amplifications. The lack of therapeutically targetable, high-frequency “driver” alterations has impeded development of targeted therapies for TNBC. TNBCs display transcriptional diversity with at least four tumor-intrinsic subtypes that include two basal-like (BL1, BL2), a mesenchymal (M) and a luminal androgen receptor (LAR) subtype. Each subtype displays unique biology and differentially responds to standard-of-care chemotherapy. Therefore, to better understand TNBC genomic alterations within molecular subtypes we have performed an integrative analysis of mutation, copy-number, gene expression, miRNA expression, reverse-phase protein array and methylation of 192 TNBC patients in The Cancer Genome Atlas and drug sensitivity of TNBC cell lines. Gene expression analysis confirmed our previous subtype-specific findings with enrichment of cell cycle, DNA replication response in BL1, Wnt and KRAS signaling BL2, androgen response in LAR and TGF-beta and mesenchymal differentiation in M. Despite having higher mutational burdens and similar copy number alterations, the BL1 and M subtypes display very different patterns of gene expression. These differences likely originate from epigenetic changes, as global methylation analysis demonstrated large hypomethylation across the genomes of M subtype. In contrast, the highly differentiated LAR subtype displayed global patterns of hypermethylation. Mutation analysis revealed enrichment of PIK3CA mutations in LAR tumors, NOTCH1, NOTCH2, NOTCH3 and FBXW7 mutations in M and BL1 tumors and activating MAPK pathway mutations (KRAS, NRAS, BRAF, MAP2K1, MAPK9 and MAP3K13) exclusive to BL2 tumors. Differential copy number analysis identified amplifications specific to the BL1 subtype (AKT3, KDR and KIT), BL2 subtype (TERT, EGFR and KRAS), M subtype (MYCN and WNT5B) and NOTCH pathway (BL1 and M). Reverse-phase protein array analysis confirmed activated MAPK signaling unique to the BL2 subtype and PI3K signaling in LAR. Cell line subtype correlations and published drug sensitivity screens verified LAR sensitivity to AR antagonists and PI3K/AKT/mTORC inhibitors, while BL2 cell models displayed sensitivity to MEK inhibitors. Subtype-specific differences in lymphocyte composition were inferred from gene expression with BL1 subtype displaying the highest CD8 levels. Despite having the greatest level of macrophages, the M subtype had the lowest ratio of M1/M2 polarized macrophages. These data suggest immune checkpoint therapies may be more effective in BL1 subtype and additional strategies targeting the immune suppressive macrophage population necessary for M tumors. Using a comprehensive multi-omics approach we defined the multi-platform genomic landscape of TNBC, identify potential therapeutic strategies and shed light on the evolutionary paths of TNBC.

Citation Format: Brian D. Lehmann, Antonio Colaprico, Jianjiao Chen, Lily Wang, Jennifer Pietenpol, Xi Chen. Integrative genomic analysis identifies distinct mutational, epigenetic and immunological patterns among triple-negative breast cancer subtypes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-301.

  • ©2019 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 79 (13 Supplement)
July 2019
Volume 79, Issue 13 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract LB-301: Integrative genomic analysis identifies distinct mutational, epigenetic and immunological patterns among triple-negative breast cancer subtypes
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract LB-301: Integrative genomic analysis identifies distinct mutational, epigenetic and immunological patterns among triple-negative breast cancer subtypes
Brian D. Lehmann, Antonio Colaprico, Jianjiao Chen, Lily Wang, Jennifer Pietenpol and Xi Chen
Cancer Res July 1 2019 (79) (13 Supplement) LB-301; DOI: 10.1158/1538-7445.AM2019-LB-301

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract LB-301: Integrative genomic analysis identifies distinct mutational, epigenetic and immunological patterns among triple-negative breast cancer subtypes
Brian D. Lehmann, Antonio Colaprico, Jianjiao Chen, Lily Wang, Jennifer Pietenpol and Xi Chen
Cancer Res July 1 2019 (79) (13 Supplement) LB-301; DOI: 10.1158/1538-7445.AM2019-LB-301
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Molecular and Cellular Biology / Genetics

  • Abstract 4772: Metabolic programming of bladder cancer: Vulnerabilities and opportunities
  • Abstract 4820: Novel protein AX-295aa encoded by circAX promotes gastric carcinogenesis by activating Wnt pathway
  • Abstract 5924: A clock gene of TIM promotes colorectal cancer tumorigenesis through binding with myosin-9
Show more Molecular and Cellular Biology / Genetics

Poster Presentations - Late-Breaking Abstracts

  • Abstract LB-319: Establishment of automated multiplex immunofluorescence T-cell panel for baseline screening of syngeneic mouse models and evaluation of T-cell infiltration in A20 syngeneic tumors treated with TAK-981, a first-in-class SUMO inhibitor
  • Abstract LB-306: Long non-coding RNA NEAT1 promotes lung metastasis of soft tissue sarcoma by regulating RNA splicing pathways
  • Abstract LB-323: Atrx deletion delays tumor formation and increases radiosensitivity of a primary mouse model of soft tissue sarcoma
Show more Poster Presentations - Late-Breaking Abstracts

Poster Presentations - Late-Breaking Research: Molecular and Cellular Biology / Genetics

  • Abstract LB-319: Establishment of automated multiplex immunofluorescence T-cell panel for baseline screening of syngeneic mouse models and evaluation of T-cell infiltration in A20 syngeneic tumors treated with TAK-981, a first-in-class SUMO inhibitor
  • Abstract LB-306: Long non-coding RNA NEAT1 promotes lung metastasis of soft tissue sarcoma by regulating RNA splicing pathways
  • Abstract LB-323: Atrx deletion delays tumor formation and increases radiosensitivity of a primary mouse model of soft tissue sarcoma
Show more Poster Presentations - Late-Breaking Research: Molecular and Cellular Biology / Genetics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement